Where Care Excellence Meets Business Success. Transform your operations today - 0333 577 0877
We are here to help 24/7.

Awarded· 10 Nov 2025

Purchase of Nanobodies and epitope mapping for grant funded project

Mhra · Tower Hamlets, London

Mhra has awarded Purchase of Nanobodies and epitope mapping for grant funded project. It is a contract for other health and social care in Tower Hamlets.

Source: Find a Tender, published 9 Dec 2025. Details are refreshed every 30 minutes.

Key dates

  1. 2025

    Contract awarded

    Proteogenix

  2. 2025

    Contract starts

  3. 2025

    Award notice published

    UK7 - Contract Details Notice · 08:34

    View notice
  4. Next

    2026

    Contract ends

    1 year after it starts

01

About this tender

In brief

Mhra has awarded Purchase of Nanobodies and epitope mapping for grant funded project. It is a contract for other health and social care in Tower Hamlets. The contract went to Proteogenix. It was awarded on 10 November 2025. The contract value is £80,000. The contract runs from 11 November 2025 to 10 November 2026. It lasts 1 year.

It is run as a below threshold - without competition. Find a Tender published it on 9 December 2025. The notice number is 080869-2025. The OCDS ID is ocds-h6vhtk-05f155.

Summary of the contracting process

The Medicines and Healthcare products Regulatory Agency (MHRA), a central government public authority based in London, United Kingdom, has completed the procurement process for a project titled "Purchase of Nanobodies and epitope mapping for grant funded project." This contract, worth €80,000 with a gross amount of €96,000, covers laboratory services, laboratory reagents, and medical analysis services crucial to the healthcare and biopharmaceutical industry.

The procurement method adopted was direct, without competition, due to the time-sensitive nature and specific expertise required for the project. The contract was awarded to Proteogenix SAS, a large supplier based in Schiltigheim, France. The document was officially signed on 10th November 2025, and the contract period is from 11th November 2025 to 10th November 2026.

The notice in full

The very important time constrains (before 20th of March 2026) attached to the awarded grant finance, for our specific objective, This supplier expertise with expressing our nanobody sequences in different formats, their speed, competitive pricing and MHRA's prior in house validation of nanobody products made by this supplier , makes this supplier in our view the only provider that can realistically meet our request within the allocated timelines.

Protein production can be outsourced from several commercial entities, but the trade for companies that have relevant and ample experience in nanobody expression, at small scale, in a cost-effective and time-saving manner to fulfil our request is limited.

Further, the timeline to complete the objectives of the project with the awarded grant finance translates into the inability to search, outsource, trial and validate the suitability of nanobodies produced by other suppliers unknown to MHRA, significantly narrowing feasible possibilities.

Lots: no lot details came through with this notice. The official notice and the tender pack have the full breakdown.

02

Key facts

Every field the notice carries. Anything it leaves blank is listed under its table.

Contract

Service
Other health and social care
Procurement type
Standard
Category
Goods
Contract period
11 Nov 2025 to 10 Nov 2026 (1 year)
Awarded to
Proteogenix
Number of suppliers
1

Procedure

Notice type
UK7 - Contract Details Notice
Procurement method
Direct
Procedure
Below threshold - without competition
Current stage
Award
Stages so far
Award
Published on
Find a Tender Service
Awardee scale
Large

Values

Contracts value
£80,000

Not stated in the notice: tender value, lots value, awards value.

Status

Tender
Complete
Lots
Complete
Awards
Active
Contracts
Active

References

Find a Tender notice
080869-2025
Open Contracting ID
ocds-h6vhtk-05f155
CPV code
33696500 - Laboratory reagents; 71900000 - Laboratory services; 85148000 - Medical analysis services
CPV division
33 - Medical equipments, pharmaceuticals and personal care products; 71 - Architectural, construction, engineering and inspection services; 85 - Health and social work services
03

Location

Mhra is based in Tower Hamlets. The area the service covers can be wider, so check the notice and the lots.
Local authority
Tower Hamlets
Town
East London
Postcode
E14 4PU
Electoral ward
Canary Wharf
Constituency
Poplar and Limehouse
Region
London
Sub-region
Tower Hamlets
Area
Inner London - East
Country
England
04

Buyer and supplier

Contracting authority

Organisation
Mhra
Category
Goods
Contact
Aun Bhatti
Address
London, E14 4PU · London · England

Not stated in the notice: phone.

Awarded supplier

Supplier
Proteogenix
Awardee scale
Large
Number of suppliers
1
Awards value
Not stated
05

Documents and links

Official sources for this notice. The tender pack itself sits on the buyer's portal.
06

Questions about Purchase of Nanobodies and epitope mapping for grant funded project

Who won the Purchase of Nanobodies and epitope mapping for grant funded project contract?

Mhra awarded the contract to Proteogenix on 10 November 2025. It is due to end on 10 November 2026, which is when a re-tender would normally follow.

How much is the Purchase of Nanobodies and epitope mapping for grant funded project contract worth?

The contract value is £80,000. The contract runs from 11 November 2025 to 10 November 2026 (1 year).

Who is the buyer for Purchase of Nanobodies and epitope mapping for grant funded project?

Mhra, based in Tower Hamlets, London. The named contact is Aun Bhatti.

Get ready for the next round

Contracts like this come back. We help care providers build the evidence, policies and case studies a buyer scores, so you are ready when the re-tender opens.

What to do next

  1. This contract has been awarded.
  2. It is due to end on 10 November 2026.
  3. A re-tender usually follows near the end.
  4. Build your evidence and case studies now.
  5. Keep your policies and training records current.